replic
vitro
concentr
low
pgmlthe
develop
ifn
clinic
use
drug
larg
disappoint
fact
attribut
partli
short
halflif
vivo
extens
side
effect
fact
mani
symptom
viral
infect
influenza
blame
endogen
ifn
releas
advers
effect
preval
therapeut
dose
includ
fever
myalgia
headach
dub
flulik
symptom
along
bone
marrow
suppress
lead
leukocytopenia
thrombocytopenia
plu
central
nervou
system
manifest
includ
depress
ifn
studi
treatment
prevent
herp
zoster
herp
simplex
cytomegaloviru
infect
success
develop
acyclovir
ganciclovir
gave
clinician
safer
effect
altern
deal
virus
ifn
also
use
treatment
multipl
sclerosi
certain
cancer
articl
review
therapeut
applic
ifn
infecti
diseas
focus
viral
infect
ifn
absorb
oral
larg
amino
acid
sequenc
suscept
proteolyt
enzym
digest
tract
howev
ifna
readili
absorb
intramuscular
subcutan
inject
rapid
absorpt
combin
short
halflif
mean
frequent
inject
need
maintain
adequ
concentr
bodi
commerci
avail
ifna
product
unit
state
chemic
attach
polyethylen
glycol
peg
enhanc
halflif
make
onceweekli
dose
possibl
coupl
make
administr
easier
also
reduc
side
effect
predict
lower
peak
concentr
exogen
cytokin
pegyl
pegasi
pegintron
obtain
escherichia
coli
recombin
method
agent
consist
natur
occur
small
protein
molecular
weight
da
consid
firstlin
option
treatment
chronic
hepat
c
viru
hcv
infect
combin
ribavirin
detail
use
other
describ
later
articl
along
list
addit
indic
approv
food
drug
administr
shown
tabl
ifna
shown
effect
treatment
symptom
aggress
case
chronic
activ
epsteinbarr
viru
elimin
infect
entir
therefor
addit
studi
would
need
perform
recommend
use
human
leukocyt
deriv
alferon
n
inject
contain
spectrum
ifn
approv
treatment
refractori
recur
condylomata
acuminata
adult
patient
lowdos
oral
version
develop
use
treatment
prevent
influenza
version
studi
human
immunodefici
viru
hiv
infect
littl
success
ifn
infergen
consid
synthet
consensu
interferon
contain
nonnatur
sequenc
ifna
amino
acid
chosen
highest
activ
viral
hepat
date
pegyl
formul
product
brought
market
ifn
includ
blackbox
warn
prescrib
inform
use
may
caus
aggrav
fatal
lifethreaten
neuropsychiatr
autoimmun
ischem
infecti
disord
patient
monitor
close
period
clinic
laboratori
evalu
therapi
withdrawn
patient
persist
sever
worsen
sign
symptom
relat
side
effect
mani
case
resolv
stop
therapi
avonex
rebif
betaseron
recombin
protein
amino
acid
respect
b
ifn
antivir
immunomodulatori
properti
use
time
limit
treatment
multipl
sclerosi
infect
actimmun
inject
use
regularli
prevent
infect
patient
chronic
granulomat
diseas
along
antibacteri
antifung
mechan
action
purpos
entir
known
longterm
studi
show
definit
benefit
ifng
also
use
salvag
therapi
mycobacteri
infect
routin
use
treatment
infect
topic
imiquimod
aldara
zyclara
cream
inher
antivir
activ
alon
instead
induc
ifna
ifnb
ifng
plu
tumor
necrosi
factor
tnf
tolllik
receptor
tlr
local
applic
extern
genit
perian
wart
result
immunomodulatori
respons
stimul
cytokin
antivir
action
caus
reduct
viral
load
wart
size
chronic
infect
hepat
b
viru
hbv
hcv
affect
million
peopl
worldwid
chronic
viral
hepat
lead
caus
cirrhosi
liver
transplant
hepatocellular
carcinoma
develop
vaccin
seri
hepat
b
along
increas
public
educ
awar
acut
infect
rate
hbv
hcv
unit
state
declin
steadili
hbv
doublestrand
dna
viru
wherea
hcv
singlestrand
rna
viru
capabl
signific
morbid
mortal
chronic
infect
exact
mechan
hepat
injuri
hbv
hcv
infect
complet
understood
asymptomat
carrier
normal
liver
transaminas
exist
like
multipl
immunemedi
mechan
result
hepatocyt
damag
oppos
viru
directli
cytotox
follow
acut
viral
infect
innat
immun
respons
initi
format
nk
cell
follow
virusspecif
cell
cytotox
lymphocyt
nk
cell
stimul
product
ifnab
promot
cellular
clearanc
viral
protein
disrupt
replic
process
follow
success
clearanc
either
spontan
treatment
ifn
peripher
cytotox
lymphocyt
tcell
respons
persist
chronic
infect
like
result
fail
innat
adapt
immun
specif
chronic
infect
hcv
associ
impair
tcell
nkcell
respons
genet
factor
also
like
influenc
progress
diseas
predisposit
advers
effect
although
abund
research
investig
immun
respons
relat
chronic
viral
hepat
mani
area
uncertainti
still
exist
standard
ifna
first
approv
ifn
viral
hepat
lack
sever
desir
pharmacokinet
properti
addit
peg
creat
ifn
slower
rate
absorpt
reduc
elimin
longer
halflif
necessit
less
frequent
dose
fewer
advers
effect
furthermor
peg
moieti
result
reduc
immunogen
steric
hinder
antigen
bind
site
although
pegyl
ifn
replac
standard
ifna
treatment
chronic
hbv
hcv
mani
patient
still
fail
respond
treatment
success
respons
depend
mani
factor
includ
limit
viral
genotyp
viral
load
degre
liver
fibrosi
chronic
hepat
b
c
treat
similarli
peginterferon
pegifn
howev
fdaapprov
unit
state
treatment
hbv
pegifn
product
administ
subcutan
inject
weekli
durat
week
depend
viral
genotyp
earli
viral
respons
treatment
hcv
dose
base
bodi
weight
mgkg
weekli
wherea
fix
dose
mgwk
ribavirin
use
combin
pegifn
treatment
hcv
exact
mechan
action
ribavirin
adjunct
antivir
agent
hcv
complet
understood
studi
propos
ribavirin
act
ifnstimul
gene
induc
improv
secondphas
viral
declin
proteas
inhibitor
boceprevir
telaprevir
recent
approv
adjunct
oral
agent
treatment
chronic
hcv
pegifn
ribavirin
date
studi
proteas
inhibitor
conduct
patient
hcv
genotyp
shown
increas
sustain
virolog
respons
svr
rate
particularli
patient
previous
unrespons
ifn
therapi
use
ifn
treatment
chronic
hbv
hcv
repres
mainstay
treatment
sever
decad
specif
mechan
behind
antivir
effect
ifn
hepat
complex
ifnstimul
gene
induc
ifn
disrupt
viral
replic
hundr
ifnstimul
gene
thought
exist
viperin
protein
kinas
r
pkr
commonli
cite
also
highli
possibl
ifnstimul
gene
work
synergist
produc
antivir
activ
lack
pkr
lead
environ
conduc
hcv
replic
though
may
good
predictor
exogen
ifn
respons
studi
ifnstimul
gene
role
determin
respond
ifn
therapi
evalu
sever
studi
addit
studi
ifnstimul
gene
express
need
clarifi
directli
involv
success
viral
respons
capac
affect
respons
whether
pharmacotherapi
direct
induct
ifnstimul
gene
help
improv
treatment
respons
chronic
hbv
infect
success
treat
ifn
monotherapi
loss
viral
dna
antibodi
format
success
outcom
associ
ifn
treatment
mechan
ifn
antivir
activ
vari
depend
hepat
antigen
hbeag
posit
hbeagneg
diseas
hbeagposit
patient
immun
respons
stimul
ifn
wherea
hbeagneg
diseas
ifn
act
directli
antivir
hbeagneg
diseas
tend
difficult
treat
associ
longer
durat
diseas
higher
likelihood
complic
cirrhosi
sever
oral
nonnucleosid
revers
transcriptas
inhibitor
also
avail
treatment
hbv
entecavir
tenofovir
adefovir
lamivudin
telbivudin
although
ifn
still
consid
firstlin
altern
provid
advantag
defin
treatment
durat
rather
potenti
lifelong
administr
oral
agent
often
use
therapi
eas
use
reduc
number
side
effect
associ
treatment
abil
hcv
evad
host
immun
respons
produc
complex
rna
viru
capabl
linger
infect
ultim
result
opportun
increas
risk
transmiss
complic
advanc
liver
diseas
much
research
regard
use
ifn
chronic
viral
hepat
focus
use
hcv
follow
treatment
ifn
declin
hcv
rna
occur
sever
phase
rapid
inhibit
rna
product
within
first
day
treatment
follow
second
slower
phase
associ
clearanc
infect
cell
interferon
infecti
diseas
immun
respons
endogen
ifn
produc
innat
immun
administ
exogen
differ
term
antivir
activ
base
phase
viral
declin
studi
shown
respons
ifnbas
treatment
hcv
may
affect
differ
ifn
signal
induct
like
hcv
mechan
avoid
recognit
innat
immun
respons
inhibit
abil
hcvinfect
cell
gener
ifn
earli
studi
conduct
nonrespond
current
therapi
show
wide
genet
divers
mani
show
common
trait
predict
nonrespons
ifn
therapi
howev
sever
major
studi
publish
associ
singlenucleotid
polymorph
snp
upstream
gene
ifn
respons
patient
hcv
genotyp
addit
evid
point
fact
polymorph
also
link
spontan
clearanc
hcv
variant
encod
type
iii
ifn
belong
interleukin
il
superfamili
function
manner
similar
type
ifn
result
ifnstimul
gene
induct
genomewid
associ
studi
conduct
ge
colleagu
evalu
hcv
genotyp
patient
major
origin
ideal
studi
result
logist
regress
show
polymorph
stronger
predictor
svr
baselin
viral
load
ethnic
degre
fibrosi
research
area
need
clearli
identifi
futur
role
genotyp
test
clarifi
whether
may
influenc
respons
therapi
hcv
genotyp
multicent
random
control
studi
mangia
colleagu
analyz
caucasian
patient
hcv
genotyp
n
n
patient
achiev
rapid
virolog
respons
rvr
genotyp
associ
svr
wherea
patient
achiev
rvr
signific
differ
svr
note
base
genotyp
time
genotyp
test
routin
recommend
hcv
patient
plan
undergo
treatment
may
futur
done
use
factor
choos
treatment
strategi
complex
viral
defens
mechan
subsequ
effect
host
respons
led
develop
chronic
infect
also
lack
viabl
vaccin
hcv
viral
polymeras
lack
proofread
capabl
creat
divers
target
vaccin
develop
addit
challeng
includ
lack
suitabl
anim
model
mimic
human
environ
medium
viral
growth
one
major
limit
ifn
therapi
advers
effect
malais
gastrointestin
effect
neuropsychiatr
effect
neutropenia
anemia
limit
effect
treatment
necessit
dosag
reduct
treatment
discontinu
newer
ifn
therapi
success
must
induc
antivir
respons
time
limit
advers
effect
albinterferon
new
ifn
therapi
current
develop
treatment
chronic
hcv
product
combin
fuse
recombin
human
albumin
one
advantag
product
requir
twice
monthli
dose
much
known
time
immunomodul
effect
albinterferon
hcv
shown
similar
svr
advers
event
rate
tradit
pegifn
use
combin
ribavirin
research
ifnl
agent
treat
hcv
also
initi
hypothes
l
ifn
may
associ
less
advers
effect
ifna
ifnl
receptor
primarili
found
hepatocyt
specif
research
new
investig
pharmacotherapi
form
pegyl
patient
hcv
genotyp
relaps
follow
tradit
treatment
pegifna
ribavirin
appear
promis
share
common
receptor
similar
sequenc
ident
openlabel
studi
conduct
patient
chronic
hcv
genotyp
design
assess
combin
ribavirin
dose
escal
studi
conduct
part
part
evalu
patient
relaps
follow
treatment
ifna
part
includ
patient
part
pegifnl
monotherapi
mgkg
mgkg
administ
subcutan
everi
week
weekli
part
rang
pegifnl
dosag
mgkg
mgkg
mgkg
mgkg
administ
weekli
combin
ribavirin
twice
daili
mg
weight
kg
mg
weight
kg
primari
outcom
safeti
toler
pharmacokinet
viral
load
reduct
evalu
secondari
end
point
commonli
report
advers
effect
pegifnl
includ
fatigu
nausea
myalgia
headach
advers
event
mild
moder
sever
four
patient
experienc
treatmentrel
toxic
requir
dose
withheld
one
patient
experienc
grade
thrombocytopen
purpura
anoth
patient
elev
alanin
aminotransferas
aspart
aminotransferas
bilirubin
level
event
consid
relat
treatment
pegifnl
aminotransferas
elev
occur
often
patient
receiv
highdos
mgkg
pegifnl
monotherapi
clinic
relev
decreas
absolut
neutrophil
count
occur
also
hemoglobin
valu
remain
consist
known
effect
patient
receiv
ribavirin
therapi
viral
activ
decreas
major
patient
relaps
previou
treatment
patient
achiev
least
greater
reduct
hcv
rna
six
patient
achiev
similar
reduct
viral
load
achiev
undetect
hcv
rna
level
kinet
data
show
linear
relationship
dose
exposur
independ
bodi
weight
may
prompt
futur
research
evalu
fix
dose
pegifnl
larger
longer
control
blind
studi
ifnl
viabl
treatment
option
hcv
need
defin
place
therapi
benefit
exist
ifn
therapi
studi
hcv
genotyp
also
need
addit
advent
proteas
inhibitor
research
necessari
evalu
direct
antivir
genotyp
interact
guid
treatment
decis
adjunct
therapi
agent
induc
restor
ifnstimul
gene
express
recent
evalu
patient
hcv
sadenosylmethionin
given
oral
evalu
openlabel
studi
patient
chronic
hcv
genotyp
consid
nonrespond
previou
ifn
ribavirin
treatment
administ
dose
mg
twice
daili
combin
mgkg
weekli
weightbas
ribavirin
mg
weight
kg
mg
weight
kg
primari
outcom
chang
firstphas
secondphas
viral
declin
treatment
respons
ifnstimul
gene
express
also
evalu
week
treatment
result
show
signific
improv
secondphas
viral
declin
assess
week
svr
also
evalu
howev
studi
power
detect
differ
virolog
respons
rate
furthermor
time
public
patient
reach
week
post
treatment
full
effect
svr
fulli
known
addit
show
greater
induct
ifnstimul
gene
includ
viperin
myxoviru
resist
protein
compar
control
advers
effect
note
mild
mostli
relat
gastrointestin
upset
like
result
lactos
tablet
prepar
addit
research
aim
investig
structureact
relationship
preliminari
pharmacokinet
studi
oral
ifn
induc
act
tlr
treatment
hcv
upper
respiratori
tract
infect
form
common
cold
caus
varieti
virus
includ
rhinoviru
coronaviru
influenza
parainfluenza
respiratori
syncyti
viru
adenoviru
coxsacki
echoviru
famili
among
other
symptom
may
includ
rhinorrhea
nasal
obstruct
cough
fever
sore
throat
diseas
usual
mild
selflimit
sever
trial
address
treatment
prevent
common
cold
therapeut
agent
ifn
one
popular
prospect
purpos
minor
benefit
deriv
counteract
advers
effect
inflict
earli
doubleblind
trial
intranas
drop
demonstr
use
sever
day
experiment
induc
rhinoviru
infect
common
cold
symptom
significantli
fewer
studi
particip
compar
placebodrop
user
administr
drop
time
daili
superior
higher
dose
given
daili
prevent
infect
shortterm
use
well
toler
obvious
realist
everyon
use
intranas
drop
time
daili
throughout
entir
cold
season
attempt
prevent
natur
infect
period
increas
acut
respiratori
tract
viru
activ
twicedaili
nasal
spray
studi
volunt
day
signific
decreas
number
rhinoviru
infect
note
type
viral
respiratori
tract
infect
includ
parainfluenza
advers
event
ifn
formul
common
placebocontrol
trial
first
week
alon
particip
receiv
ifn
spray
report
noseble
number
increas
end
studi
provid
ifn
prophylaxi
famili
member
infect
common
cold
virus
target
approach
therapi
sever
studi
address
use
ifn
nasal
spray
scenario
seven
day
use
significantli
reduc
rhinoviru
infect
differ
trial
compar
placebo
individu
vs
famili
vs
p
studi
lower
dose
given
shorter
cours
overal
intranas
dose
ifn
need
protect
upper
respiratori
tract
infect
appear
caus
signific
unwant
effect
infect
coronaviru
respiratori
syncyti
viru
also
object
investig
nasal
spray
littl
success
studi
intranas
human
lymphoblastoid
wellferon
suggest
lower
prophylact
activ
influenza
rhinoviru
result
prophylact
trial
ifn
common
cold
virus
favor
use
treatment
infect
seem
logic
applic
biolog
respons
modifi
although
benefit
origin
seen
twicedaili
intranas
drop
treatment
experiment
induc
rhinoviru
advantag
clear
intranas
spray
use
daili
day
treat
natur
infect
increas
rate
blood
mucu
note
particip
receiv
intervent
ifn
group
experienc
secondari
complic
requir
prescript
antibiot
investig
conclud
intranas
ifn
ineffect
treat
common
cold
associ
clinic
signific
side
effect
similar
trial
ifnbserin
ifng
formul
although
initi
posit
shown
equal
disappoint
clinic
result
even
though
prospect
studi
ifn
upper
respiratori
tract
infect
appear
limit
one
modern
trial
demonstr
ad
benefit
intranas
combin
antihistamin
chlorpheniramin
nonsteroid
antiinflammatori
drug
ibuprofen
reduc
common
cold
symptom
show
least
one
group
still
interest
studi
topic
investig
also
recent
begun
research
altern
therapeut
approach
rhinoviru
infect
use
ifn
tnfa
induc
imiquimod
applic
intranas
cream
primat
shown
promis
result
term
enhanc
cytokin
respons
human
trial
yet
publish
human
papillomavirus
hpv
known
caus
cervic
cancer
also
respons
genit
wart
hpv
nonenvelop
doublestrand
dna
virus
invad
mucos
epitheli
tissu
sexual
contact
infect
partner
estim
sexual
activ
american
popul
infect
hpv
one
point
live
hyperprolifer
infect
cell
occur
lead
genit
wart
cancer
cervix
vagina
vulva
peni
among
other
differ
type
hpv
approxim
infect
genit
mucosa
fifteen
carcinogen
type
hpv
identifi
associ
cervic
cancer
two
vaccin
recent
introduc
prevent
infect
common
highrisk
type
hpv
one
vaccin
also
induc
protect
preval
hpv
type
low
risk
malign
instead
caus
genit
wart
hpv
abil
persist
stratifi
epithelia
decad
mechan
avoid
immun
erad
ifn
play
larg
role
cycl
ifn
normal
secret
keratinocyt
hpv
reduc
express
introduct
lowlevel
ifn
actual
increas
earli
gene
transcript
hpv
replic
may
explain
use
agent
therapeut
mix
result
overal
outcom
posit
often
case
genit
wart
reduct
hpv
lesion
associ
cancer
studi
compar
vitro
activ
oncogen
demonstr
increas
concentr
alway
correl
stepwis
inhibit
hpv
replic
meanwhil
metaanalysi
recent
analyz
local
use
system
ifn
genit
wart
seven
random
studi
ifn
intralesion
inject
topic
gel
met
criteria
inclus
overal
benefit
complet
respons
rate
placebo
vs
rel
risk
confid
interv
howev
differ
outcom
trial
compar
system
ifn
placebo
comparison
clearanc
genit
perian
wart
occur
patient
topic
ifn
induc
imiquimod
usual
week
use
imiquimod
cream
aldara
appli
affect
area
time
week
week
wherea
newer
cream
zyclara
appli
daili
littl
week
treat
extern
genit
wart
caus
hpv
system
ifn
therapi
may
use
hpv
affect
area
bodi
anogenit
region
success
treatment
system
pegifna
topic
retinoid
report
mucos
carcinoma
epidermodysplasia
verruciformi
genet
abnorm
lead
persist
widespread
hpv
infect
skin
recurr
respiratori
hpv
infect
also
effect
treat
ifna
patient
although
effect
viral
load
replic
followup
patient
treat
ifna
recurr
respiratori
papillomatosi
confirm
better
respons
rate
higher
likelihood
malign
transform
recurr
conjunctiv
papilloma
topic
plu
system
intralesion
ifn
effect
partial
excis
rapid
resolut
signific
hpvassoci
wart
hand
foot
face
also
occur
hivinfect
patient
antiretrovir
treat
hepat
c
ribavirin
case
report
treatment
topic
ifn
induc
imiquimod
shown
promis
use
focal
epitheli
hyperplasia
heck
diseas
rare
disord
caus
specif
type
hpv
affect
oral
mucosa
primarili
children
addit
imiquimod
cream
use
success
treatment
plantar
wart
smoother
flatter
manifest
foot
interest
oral
cimetidin
along
reduc
stomach
acid
also
induc
product
ifng
elimin
viral
wart
patient
futur
improv
applic
effect
topic
ifn
may
becom
realiti
could
provid
valuabl
treatment
hpv
infect
without
system
side
effect
current
inject
formul
adjuv
adjuvar
latin
help
substanc
augment
immunogen
antigen
mix
antigen
use
vaccin
adjuv
stimul
granuloma
macrophagerich
mass
enhanc
costimulatori
signal
stimul
nonspecif
lymphocyt
product
prolong
antigen
concentr
site
lymphocyt
exposur
induc
cytokin
research
vaccin
develop
shown
one
promis
use
ifn
adjuv
specif
antigen
prophylact
vaccin
toporovski
colleagu
provid
current
review
use
ifna
ifnb
ifng
ifnl
vaccin
studi
focu
primarili
murin
avian
porcin
nonhuman
speci
regardless
speci
use
ifn
adjuv
seem
improv
efficaci
safeti
vaccin
provid
immunomodulatori
effect
stimul
thelper
respons
human
ifna
predominantli
produc
plasmacytoid
dendrit
cell
play
larg
role
bodi
immun
respons
virus
induc
plasma
cell
differenti
b
cell
caus
increas
serum
level
influenzaspecif
immunoglobulin
channel
antigenpres
cell
apc
site
infect
research
ifna
adjuv
activ
subsequ
use
approv
vaccin
seem
indic
potent
adjuv
mix
influenza
vaccin
inject
intramuscularli
highli
effect
adjuv
oromucos
administr
recombin
ifna
like
natur
oromucos
ifn
product
shown
provid
immun
viral
infect
tumor
cell
growth
nonrespond
low
respond
previou
vaccin
show
improv
immunoglobulin
respons
recombin
ifna
hbv
vaccin
although
research
also
focus
class
ifn
adjuv
thu
far
yield
result
promis
ifna
use
ifnb
yield
mix
result
ifng
use
primarili
dna
vaccin
even
less
known
use
ifnl
vaccin
nevertheless
use
ifn
adjuv
show
great
promis
augment
vaccin
effici
continu
top
prioriti
develop
vaccin
ifn
test
repeatedli
infecti
diseas
inject
use
mostli
treatment
viral
hepat
c
prevent
infect
patient
chronic
granulomat
diseas
clinic
intralesion
ifn
topic
induc
effect
reduc
manifest
genit
wart
elimin
cancercaus
hpv
bodi
ifn
prove
consist
effect
treatment
respiratori
tract
infect
common
cold
influenza
virus
prophylact
use
current
feasibl
sever
quantiti
advers
effect
system
ifn
therapi
make
unattract
mani
use
sever
infect
includ
herp
simplex
herp
zoster
cytomegaloviru
even
viral
hepat
b
effect
pharmacolog
treatment
ifn
success
use
vaccin
adjuv
research
may
allow
addit
use
applic
futur
